Reading Performance in Geographic Atrophy: Comparison of Different Reading Speed Measures for Capturing Longitudinal Changes
- PMID: 40124312
- PMCID: PMC11930067
- DOI: 10.1016/j.xops.2024.100700
Reading Performance in Geographic Atrophy: Comparison of Different Reading Speed Measures for Capturing Longitudinal Changes
Abstract
Purpose: To compare different reading speed measures for capturing longitudinal visual function changes in eyes with geographic atrophy (GA) secondary to age-related macular degeneration.
Design: Analysis of data from Chroma (NCT02247479) and Spectri (NCT02247531), 2 identically designed, phase III, double-masked, randomized controlled clinical trials for lampalizumab.
Participants: Nine hundred forty participants aged ≥50 years old with bilateral GA, who completed monocular testing of reading speed at ≥3 visits over >1-year follow-up.
Methods: Monocular reading speed was assessed using the Minnesota Low-Vision Reading Test (MNRead). Four different reading speed measures were derived and compared: reading speed of the fastest sentence read (RS1), mean reading speed of the 3 fastest sentences read (RS2), mean reading speed of the sentences larger than the critical print size (RS3), and mean reading speed of the 10 largest print sizes (termed the Reading Accessibility Index [ACC]).
Main outcome measures: Coefficient of variation (CV), with lower values reflecting better performance of a measure for capturing longitudinal change relative to interindividual variability.
Results: All 4 reading speed measures showed a significant decline at 48, 72, and 96 weeks from baseline (P < 0.001 for all). The CVs for ACC and RS2 (204% and 208%, respectively) were lower than for RS1 (255%; P ≤ 0.002) and RS3 (224%; P ≥ 0.068) for detecting change from baseline at 48 weeks, but these 2 measures were not significantly different from each other (P = 0.362). There were also statistically significant, but weak, negative correlations between the change from baseline at 48 weeks for all 4 reading speed measures with GA area on fundus autofluorescence imaging (ρ = -0.13 to -0.15; all P < 0.001).
Conclusions: The mean reading speed derived from either the 10 print sizes found in everyday life (ACC) or the fastest 3 sentences read (RS2) was better than 2 widely used measures (RS1 and RS3) at capturing progressive functional decline in eyes with GA and may be the preferred measures in future clinical trials and studies. All reading speed measures also showed an expected progressive decline over time, but they only showed a weak correlation with GA growth.
Financial disclosures: Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.
Keywords: Age-related macular degeneration; Geographic atrophy; Reading speed; Visual acuity; Visual function.
© 2025 by the American Academy of Ophthalmologyé.
Figures



Similar articles
-
Visual Function Decline Resulting from Geographic Atrophy: Results from the Chroma and Spectri Phase 3 Trials.Ophthalmol Retina. 2020 Jul;4(7):673-688. doi: 10.1016/j.oret.2020.01.019. Epub 2020 Jan 31. Ophthalmol Retina. 2020. PMID: 32199866 Clinical Trial.
-
Efficacy and Safety of Lampalizumab for Geographic Atrophy Due to Age-Related Macular Degeneration: Chroma and Spectri Phase 3 Randomized Clinical Trials.JAMA Ophthalmol. 2018 Jun 1;136(6):666-677. doi: 10.1001/jamaophthalmol.2018.1544. JAMA Ophthalmol. 2018. PMID: 29801123 Free PMC article. Clinical Trial.
-
Macular Sensitivity Endpoints in Geographic Atrophy: Exploratory Analysis of Chroma and Spectri Clinical Trials.Ophthalmol Sci. 2023 Jun 12;4(1):100351. doi: 10.1016/j.xops.2023.100351. eCollection 2024 Jan-Feb. Ophthalmol Sci. 2023. PMID: 37869030 Free PMC article.
-
Complement inhibitors for age-related macular degeneration.Cochrane Database Syst Rev. 2023 Jun 14;6(6):CD009300. doi: 10.1002/14651858.CD009300.pub3. Cochrane Database Syst Rev. 2023. PMID: 37314061 Free PMC article. Review.
-
The Progression of Geographic Atrophy Secondary to Age-Related Macular Degeneration.Ophthalmology. 2018 Mar;125(3):369-390. doi: 10.1016/j.ophtha.2017.08.038. Epub 2017 Oct 27. Ophthalmology. 2018. PMID: 29110945 Review.
Cited by
-
Geographic atrophy: Understanding the relationship between structure and function.Asia Pac J Ophthalmol (Phila). 2025 May-Jun;14(3):100207. doi: 10.1016/j.apjo.2025.100207. Epub 2025 May 19. Asia Pac J Ophthalmol (Phila). 2025. PMID: 40398512 Review.
References
-
- Sarks J., Sarks S., Killingsworth M. Evolution of geographic atrophy of the retinal pigment epithelium. Eye. 1988;2:552–577. - PubMed
-
- Heier J.S., Lad E.M., Holz F.G., et al. Pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration (OAKS and DERBY): two multicentre, randomised, double-masked, sham-controlled, phase 3 trials. Lancet. 2023;402:1434–1448. - PubMed
-
- Khanani A.M., Patel S.S., Staurenghi G., et al. Efficacy and safety of avacincaptad pegol in patients with geographic atrophy (GATHER2): 12-month results from a randomised, double-masked, phase 3 trial. Lancet. 2023;402:1449–1458. - PubMed
LinkOut - more resources
Full Text Sources